Background In invasive aspergillosis, the duration of neutropenia is an accepted risk factor, and recovery from neutropenia is generally associated with a favourable outcome. However, the rapidity of granulocyte recovery may rarely be associated with adverse sequelae. The purpose of this study was to define the relationship between neutrophil (polymorphonuclear, PMN) recovery after chemotherapy-induced bone marrow aplasia and the occurrence of severe pulmonary complications (haemoptysis, pneumothorax and death) in patients with haematological malignancies who developed invasive fungal pneumonias.
Introduction
Invasive pulmonary mycoses, especially with Aspergillus spp., are a major cause of morbidity and mortality in immunocompromised hosts with protracted neutropenia [1] [2] [3] [4] [5] [6] [7] , in patients with defects of phagocyte function [8] and in patients treated with high dosages of steroids [9, 10] , because steroids inhibit the bactericidal and fungicidal activities of phagocytes [11, 12] . In patients with leukaemia, the prognosis of pulmonary aspergillosis is frequently related to the status of the underlying disease (i.e. whether the patient is in remission or relapse), and whether polymorphonuclear neutrophil (PMN) recovery occurs or is imminent. Indeed, it is frequently assumed that improvement in invasive pulmonary mycosis will occur if the patient achieves remission and/or haematological recovery. However, the massive leucocytosis that follows the period of profound neutropenia could paradoxically represent a hazard for some leukaemia patients with invasive fungal pneumonia. For example, three groups [13] [14] [15] observed the appearance of cavitary lesions and massive haemoptysis concomitant with bone marrow recovery. The aim of this study was to define whether a significant relationship between neutrophil recovery and the evolution of pulmonary infiltrates (i.e. cavitation and subsequent events such as life-threatening haemorrhage) exists and to determine the possible predictive factors for the outcome, in particular the rate of PMN recovery, expressed as PMN mL ¹1 on the fifth day after profound neutropenia (PMN < 100 mL ¹1 ) and antifungal therapy.
Methods

Patients
Twenty consecutive neutropenic patients (10 women, 10 men, mean age 42 years, range 16-69 years) with acute leukaemia or high-grade lymphoma (acute myelogenous leukaemia 13, acute lymphoblastic leukaemia 4, blastic transformation of chronic myelogenous leukaemia 1, nonHodgkin lymphoma 2) who had developed pulmonary infiltrates that were proven or likely to be due to fungal infection [14] were studied. Aspergillus pneumonia was defined as proven if histologically documented either in vivo or at autopsy, or as probable if diagnosed according to the criteria of Robertson & Larson [16] : clinical evidence and radiological evidence, i.e. presence of cavitation with 'fungus ball' on chest radiograph and/or findings on computerized tomography (CT) scan compatible with aspergillar lesions (long lesions with 'halo sign' and/or 'air crescent sign'), and/or microbiological evidence (sputum cultures and bronchoalveolar larage) but not histological evidence. Possible Aspergillus pneumonia was not considered. The patients were admitted to single-bed or double-bed rooms with reverse isolation precautions. The patients had no evidence of bacterial, viral or protozoal infections. All patients had normal platelet counts and normal coagulation tests. The first 17 episodes of pulmonary fungal infection occurred in patients who had not received antifungal prophylaxis, and the last three episodes occurred in patients who had received prophylactic oral itraconazole (200 mg daily) and nasal amphotericin B as reported elsewhere [17] . When patients became febrile and neutropenic they were evaluated and started on broad-spectrum parenteral antibiotic therapy. Patients with persistent fever (i.e. after a week of antibiotics) or who developed pulmonary infiltrate(s) were given i.v. amphotericin B (1 mg kg ¹1 per day). Patients did not receive granulocyte (G) or granulocyte-macrophage (GM) colony-stimulating factor (CSF).
Laboratory and clinical studies
Leucocyte, granulocyte and platelets counts were monitored daily. All patients had PMN counts less than 100 mL
¹1
. Dosages of i.v. amphotericin B on days 5 and 8 after neutrophil recovery were recorded. Chest radiography was carried out at least twice a week. The time of appearance of cavitation and the time of occurrence of pulmonary 'events' (either the appearance of severe haemoptysis and/ or pneumothorax) in relation to PMN recovery was examined. In cases of fatal outcome, autopsy was performed.
Statistical analysis
Statistical analysis was performed by a multiplicative logistic model [18] : PMN count and amphotericin B dosage at 8 days were considered as independent variables, whereas the dependent variable was either the occurrence of a pulmonary event or death. The results of the analysis were synthesized using odds ratios, which were computed on the basis of an increase in the value of 1 SD. As the PMN count usually follows a Poisson distribution, a square-root transformation was applied to this variable before subsequent analysis [19] . The PMN count used as the cut-off to distinguish between low risk and high risk of pulmonary events was assessed by analysing clinical and laboratory data and using a decision level plot [20] . Table 1 reports the main clinical data of the 20 patients studied. Before the appearance of fungal pneumonia, all 20 patients were profoundly neutropenic (PMN < 100 mL ¹1 ) as a consequence of previous chemotherapy. The granulocyte recovery always followed a prolonged neutropenia period. The median duration of neutropenia was 21 days (range 16-42 days). In 90% (18/20) of cases cavitation occurred in association with PMN recovery.
Results
As shown in Fig. 1 , the rapidity of PMN recovery was critical for adverse pulmonary events (haemoptysis, pneumothorax). In fact six out of eight patients who had rapid PMN recovery (from < 100 mL ¹1 to 4500 mL ¹1 in 5 days) developed an event. In contrast, of 12 patients without PMN recovery or with slow PMN recovery, 2 out of 12 (17%) had an event (P < 0·001).
The optimal cut-off point to distinguish between patients at low risk of a pulmonary event and patients at high risk was assessed using a decision level plot and was found to be 4500 PMN mL ¹1 . Five of the eight patients (62·5%) who experienced a pulmonary event died because of haemoptysis (4) or haemoptysis plus pneumothorax (1), whereas none of the 12 patients who did not develop a pulmonary complication died. Table 2 shows that the risk of death was larger in the presence of rapid neutrophil recovery, although the difference was not statistically significant, probably because of the small number of cases (P ¼ 0·111).
The total dosages of amphotericin B received on day 8 are reported in Table 1 , together with the occurrence of events and deaths.
Mortality was lower for patients who received a higher (> 500 mg) total dose of i.v. amphotericin B at PMN recovery than those who received lower dosages of amphotericin B (14% vs. 50%, respectively), although the difference did not reach conventional significance.
Discussion
A recent review of the literature [15] showed that massive haemoptysis is an undervalued cause of death in patients with acute leukaemia in remission and pulmonary filamentous mycosis. Our results are in agreement with this, and the data presented in this paper allow us to address the question of the possible mechanism(s) of severe pulmonary complications in these patients. Just as the onset and duration of neutropenia are widely accepted risk factors for infections, including invasive mycoses, recovery from neutropenia is also generally associated with an improved outcome. Although these two tenets are true for the vast majority of patients, there may be times when granulocyte recovery may actually be associated with adverse sequelae [13, 14] . The pulmonary complications we described suggest that this may be true for patients with invasive mycosis, and this may have particular relevance for occasions when rapid granulocyte recovery occurs.
The pathogenesis of pulmonary cavitation is probably related to both the tissue damage produced by the organism and to the host reaction. As already pointed out by Panos et al. [21] , a fatal haemoptysis in patients with fungal pneumonia may occur by two different mechanisms. During profound neutropenia, the pulmonary lesions may be due to direct vascular damage by the fungus, possibly through the release of proteolytic enzymes by Aspergillus itself. A second mechanism is the disruption of vascular structures by necrotizing acute inflammation. We suggest that the second mechanism is prevalent in patients who are affected by pulmonary complications during or just after bone marrow recovery. A massive influx of PMNs into the site of fungal lesions, attracted and primed by chemotactic factors released by Aspergillus and by humoral inflammatory mediators, may be detrimental for the residual healthy pulmonary tissue [22, 23] . We have previously demonstrated that mature neutrophils that regenerate after marrow aplasia are functionally active and produce oxygen radicals when suitably activated [24] . It is highly conceivable that the interaction between functional PMN and a large amount of infectious agent and cell debris induces the stimulation of cell metabolism with release of reactive oxygen intermediates and proteolytic enzymes, including collagenase and elastase. In addition, stimulated neutrophils may inactivate protease inhibitors [25] and plasminogen activator inhibitor [26] . As a consequence, an outburst of the inflammatory process develops in a few hours or a few days, which can eventually propagate to the neighbouring structures that have been invaded by Aspergillus, and causes massive haemorrhage and/or pleural rupture. Our experience demonstrates that the degree of lung damage and the occurrence of haemorrhage and pneumothorax are strongly correlated with the blood PMN count and the rapidity of their recovery. The risk of death was not significantly affected by the extent of PMN recovery, probably because of the low number of subjects: 20 patients and 5 casualties. Larger samples are needed to clarify this point.
The increased frequency of pulmonary events when neutrophil recovery is higher than 4500 PMN mL ¹1 in 5 days may have particular relevance for the management of these high-risk patients. Three major points can be discussed in this respect. First, the awareness of the high probability of the occurrence of pulmonary events can lead the clinician to make ready all the emergency procedures, including surgical intervention, for the treatment of this kind of life-threatening event. Second, although we could not demonstrate significant differences in outcome based on the dosage of amphotericin B, probably because of the limited number of cases, data from the literature stress the importance of an early and intensive amphotericin B use in the presence of fever not responsive to broad spectrum antibiotics, mainly if associated with pulmonary infiltrates of suspected fungal origin [27, 28] .
Finally, the clear correlation between PMN recovery and pulmonary complications connected with aspergilloma raises the question about the use of haemopoietic growth factors. Our data, together with those of Groll et al. [29] , suggest that in some patients the use of these agents, which are known to prime the neutrophil respiratory burst [30] , may be detrimental. Accordingly, the beneficial effects generally associated with phagocyte recovery may need to be modulated in patients with invasive pulmonary aspergillosis.
In conclusion, the present work supports the view that abrupt neutrophilia, after a period of neutropenia and associated fungal infections, can cause more lung damage than when the return of neutrophils is relatively slower, and indicates that the rate of PMN recovery is a clinically significant variable in the follow-up of patients recovering from bone marrow ablative chemotherapy. *PMNs more than 4500 mL vs. less than 4500 mL ¹1 . †Amphotericin B more than 500 mg vs. less than 500 mg.
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